Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of LAG525 Alone and with PDR001 in Advanced Malignancies
jRCT2080223249Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of ieramilimab and spartalizumab in Nonhematologic neoplasms and solid tumor (3 arms), sponsored by Novartis. Started Jun 2016; status: completed.
02
Drugs
ieramilimabspartalizumab
03
Conditions
Nonhematologic neoplasmssolid tumor
Beyond the preview
Go deeper on jRCT2080223249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223249.